iShares MSCI Japan ETF vs Edgewise Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Japan ETF trades at $94.77 (market cap $23.55B), while Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B). The key difference: iShares MSCI Japan ETF is far larger — about 6× Edgewise Therapeutics Inc. Common Stock's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Edgewise Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Edgewise Therapeutics Inc. Common Stock for 0 Days on average.
| EWJ | EWTX | |
|---|---|---|
Market Cap | $23.55B | $3.94B |
Volume | 1,896,806 | 810,104 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $48.35 |
52-Week Low | $79.49 | $14.89 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $3.48B |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32 with no significant daily movement. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. The ETF benefits from Japan's economic developments including recent Bank of Japan rate hikes and fiscal stimulus measures. Support and resistance levels cluster tightly around the current price, indicating potential for breakout movement.
The outlook for EWJ appears cautiously optimistic as Japan navigates monetary policy normalization while maintaining growth stimulus. Investment opportunities include exposure to Japan's AI and semiconductor sectors, though risks persist from yen volatility, rising bond yields, and global macroeconomic pressures. The ETF's performance relative to the S&P 500 in 2026 suggests international diversification benefits.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →